A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors
This is a dose escalation study that will assess the safety and efficacy of LCL161 in combination with weekly paclitaxel in adult patients with advanced solid tumors.
Solid Tumors
DRUG: LCL161|DRUG: Paclitaxel
Maximum tolerated dose (MTD)/RP2D of LCL161 when administered in combination with once weekly paclitaxel, 24 months
Safety and tolerability of the combination, including acute and chronic toxicities, 24 months|Pharmacokinetics of both LCL161 and paclitaxel when administered in combination (AUC0-âˆž, Cmax, tmax and other parameters as appropriate), 24 months|Preliminary anti-tumor activity associated with this combination treatment, 24 months|Target inhibition, cell death, and cytokines in surrogate and tumor tissues, 24 months
This is a dose escalation study that will assess the safety and efficacy of LCL161 in combination with weekly paclitaxel in adult patients with advanced solid tumors.